These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 36297417)

  • 21. Effect of Polysorbate 20 and Polysorbate 80 on the Higher-Order Structure of a Monoclonal Antibody and Its Fab and Fc Fragments Probed Using 2D Nuclear Magnetic Resonance Spectroscopy.
    Singh SM; Bandi S; Jones DNM; Mallela KMG
    J Pharm Sci; 2017 Dec; 106(12):3486-3498. PubMed ID: 28843351
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Application of 2D-NMR with room temperature NMR probes for the assessment of the higher order structure of filgrastim.
    Brinson RG; Ghasriani H; Hodgson DJ; Adams KM; McEwen I; Freedberg DI; Chen K; Keire DA; Aubin Y; Marino JP
    J Pharm Biomed Anal; 2017 Jul; 141():229-233. PubMed ID: 28454057
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative Analysis of One-Dimensional Protein Fingerprint by Line Shape Enhancement and Two-Dimensional
    Elliott KW; Ghasriani H; Wikström M; Giddens JP; Aubin Y; Delaglio F; Marino JP; Arbogast LW
    Anal Chem; 2020 May; 92(9):6366-6373. PubMed ID: 32267681
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Simple NMR methods for evaluating higher order structures of monoclonal antibody therapeutics with quinary structure.
    Chen K; Long DS; Lute SC; Levy MJ; Brorson KA; Keire DA
    J Pharm Biomed Anal; 2016 Sep; 128():398-407. PubMed ID: 27344629
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mapping monoclonal antibody structure by 2D 13C NMR at natural abundance.
    Arbogast LW; Brinson RG; Marino JP
    Anal Chem; 2015 Apr; 87(7):3556-61. PubMed ID: 25728213
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Automated, High-Throughput Infrared Spectroscopy for Secondary Structure Analysis of Protein Biopharmaceuticals.
    Liu LL; Wang L; Zonderman J; Rouse JC; Kim HY
    J Pharm Sci; 2020 Oct; 109(10):3223-3230. PubMed ID: 32758548
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Principal Component Analysis of 1D 1H Diffusion Edited NMR Spectra of Protein Therapeutics.
    Elliott KW; Delaglio F; Wikström M; Marino JP; Arbogast LW
    J Pharm Sci; 2021 Oct; 110(10):3385-3394. PubMed ID: 34166704
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chemical Structure and Composition of Major Glycans Covalently Linked to Therapeutic Monoclonal Antibodies by Middle-Down Nuclear Magnetic Resonance.
    Peng J; Patil SM; Keire DA; Chen K
    Anal Chem; 2018 Sep; 90(18):11016-11024. PubMed ID: 30102512
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Assessment of the higher order structure of Humira®, Remicade®, Avastin®, Rituxan®, Herceptin®, and Enbrel® by 2D-NMR fingerprinting.
    Hodgson DJ; Ghasriani H; Aubin Y
    J Pharm Biomed Anal; 2019 Jan; 163():144-152. PubMed ID: 30296716
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Assessment of higher order structure comparability in therapeutic proteins using nuclear magnetic resonance spectroscopy.
    Amezcua CA; Szabo CM
    J Pharm Sci; 2013 Jun; 102(6):1724-1733. PubMed ID: 23568791
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Development of antibody arrays for monoclonal antibody Higher Order Structure analysis.
    Wang X; Li Q; Davies M
    Front Pharmacol; 2013; 4():103. PubMed ID: 23970865
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combining heteronuclear correlation NMR with spin-diffusion to detect relayed Cl-H-H and N-H-H proximities in molecular solids.
    Raval P; Trébosc J; Pawlak T; Nishiyama Y; Brown SP; Manjunatha Reddy GN
    Solid State Nucl Magn Reson; 2022 Aug; 120():101808. PubMed ID: 35780556
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Utility of High Resolution 2D NMR Fingerprinting in Assessing Viscosity of Therapeutic Monoclonal Antibodies.
    Majumder S; Bhattacharya DS; Langford A; Ignatius AA
    Pharm Res; 2022 Mar; 39(3):529-539. PubMed ID: 35174433
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Profiling formulated monoclonal antibodies by (1)H NMR spectroscopy.
    Poppe L; Jordan JB; Lawson K; Jerums M; Apostol I; Schnier PD
    Anal Chem; 2013 Oct; 85(20):9623-9. PubMed ID: 24006877
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Investigating Crystalline Protein Suspension Formulations of Pembrolizumab from MAS NMR Spectroscopy.
    Li M; Reichert P; Narasimhan C; Sorman B; Xu W; Cote A; Su Y
    Mol Pharm; 2022 Mar; 19(3):936-952. PubMed ID: 35107019
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Characterizing monoclonal antibody formulations in arginine glutamate solutions using
    Kheddo P; Cliff MJ; Uddin S; van der Walle CF; Golovanov AP
    MAbs; 2016 Oct; 8(7):1245-1258. PubMed ID: 27589351
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chemometric Methods to Quantify 1D and 2D NMR Spectral Differences Among Similar Protein Therapeutics.
    Chen K; Park J; Li F; Patil SM; Keire DA
    AAPS PharmSciTech; 2018 Apr; 19(3):1011-1019. PubMed ID: 29110294
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Minor N-Glycan Mapping of Monoclonal Antibody Therapeutics Using Middle-Down NMR Spectroscopy.
    Zhuo Y; Keire DA; Chen K
    Mol Pharm; 2021 Jan; 18(1):441-450. PubMed ID: 33305950
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Monitoring size and oligomeric-state distribution of therapeutic mAbs by NMR and DLS: Trastuzumab as a case study.
    Joshi S; Khatri LR; Kumar A; Rathore AS
    J Pharm Biomed Anal; 2021 Feb; 195():113841. PubMed ID: 33371967
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.